• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Genzyme

Genzyme

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme ’s Oral Therapy for Gaucher Disease Type 1

    European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme ’s Oral Therapy for Gaucher Disease Type 1

  2. Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

    Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

  3. Leerink Partners Names James Boylan President

    Leerink Partners Names James Boylan President

  4. Research and Markets: Global Orphan Drug Pipeline & Regulatory Insight 2015

    Research and Markets: Global Orphan Drug Pipeline & Regulatory Insight 2015

  5. Research and Markets: European Orthopedic Soft Tissue Repair & Sports Medicine Market 2014-2020

    Research and Markets: European Orthopedic Soft Tissue Repair & Sports Medicine Market 2014-2020

  6. Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

    Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

  7. Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

    Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

  8. Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer

    Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer

  9. Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

    Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract

  10. Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

    Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.